Pasireotide
- Generic Name
- Pasireotide
- Brand Names
- Signifor
- Drug Type
- Small Molecule
- Chemical Formula
- C58H66N10O9
- CAS Number
- 396091-73-9
- Unique Ingredient Identifier
- 98H1T17066
- Background
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
- Indication
For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
- Associated Conditions
- Acromegaly, Cushing's Disease
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
- Conditions
- Acromegaly
- Interventions
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT00088582
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸New York University/VA Medical Center, New York, New York, United States
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT00088595
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Louisiana State University Medical Center, New Orleans, Louisiana, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.